Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol

George N. Ioannou, Sum P. Lee, Peter S. Linsley, Vivian Gersuk, Matthew M. Yeh, Yen‐Ying Chen, Yi‐Jen Peng, Moumita Dutta, Gabby Mascarinas, Bruk Molla, Julia Yue Cui, Christopher Savard – 23 November 2021 – Proprotein convertase subtilisin/kexin type 9 (Pcsk9) binds to hepatic low‐density lipoprotein receptor (LDLR) and induces its internalization and degradation. Pcsk9 inhibition increases LDLR expression by hepatocytes, which causes increased uptake of circulating LDL, thereby reducing plasma LDL‐cholesterol.

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer Cells

Darko Castven, Carolin Czauderna, Diana Becker, Sharon Pereira, Jennifer Schmitt, Arndt Weinmann, Viral Shah, Jovana Hajduk, Friederike Keggenhoff, Harald Binder, Tobias Keck, Stefanie Heilmann‐Heimbach, Marcus A. Wörns, Snorri S. Thorgeirsson, Kai Breuhahn, Peter R. Galle, Jens U. Marquardt – 23 November 2021 – Induction of neoangiogenesis is a hallmark feature during disease progression of hepatocellular carcinoma (HCC). Antiangiogenetic compounds represent a mainstay of therapeutic approaches; however, development of chemoresistance is observed in the majority of patients.

Lipidomics and Redox Lipidomics Indicate Early Stage Alcohol‐Induced Liver Damage

Jeremy P. Koelmel, Wan Y. Tan, Yang Li, John A. Bowden, Atiye Ahmadireskety, Andrew C. Patt, David J. Orlicky, Ewy Mathé, Nicholas M. Kroeger, David C. Thompson, Jason A. Cochran, Jaya Prakash Golla, Aikaterini Kandyliari, Ying Chen, Georgia Charkoftaki, Joy D. Guingab‐Cagmat, Hiroshi Tsugawa, Anmol Arora, Kirill Veselkov, Shunji Kato, Yurika Otoki, Kiyotaka Nakagawa, Richard A. Yost, Timothy J. Garrett, Vasilis Vasiliou – 22 November 2021 – Alcoholic fatty liver disease (AFLD) is characterized by lipid accumulation and inflammation and can progress to cirrhosis and cancer in the liver.

Blood Pressure Variability Early After Liver Transplantation Predicts Long‐Term Mortality

Katie Truitt, Kevin Chen, Yuichiro Yano, Dyanna L. Gregory, Lisa B. VanWagner – 21 November 2021 – Cardiovascular disease is a leading cause of mortality after liver transplantation (LT). Elevated blood pressure (BP) in LT recipients (LTRs) is associated with increased cardiovascular events (CVEs) and decreased survival. Increased visit‐to‐visit BP variability in the general population is associated with adverse outcomes. Whether BP variability is associated with adverse outcomes in LTRs is unknown.

Outcome of Extended Right Lobe Liver Transplantations

Vladimir J. Lozanovski, Christian Unterrainer, Bernd Döhler, Caner Süsal, Arianeb Mehrabi – 21 November 2021 – Split‐liver transplantation offers a solution to the organ shortage problem. However, the outcomes of extended right lobe liver transplantation (ERLT) and whether it is a suitable alternative to full‐size liver transplantation (FSLT) remain controversial. We compared the outcomes of ERLT and FSLT in adult recipients of 43,409 first deceased donor liver transplantations using Cox regression.

Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study

Luca Valenti, Serena Pelusi, Alessio Aghemo, Sara Gritti, Luisa Pasulo, Cristiana Bianco, Claudia Iegri, Giuliana Cologni, Elisabetta Degasperi, Roberta D’Ambrosio, Paolo Poggio, Alessandro Soria, Massimo Puoti, Isabella Carderi, Marie Graciella Pigozzi, Canio Carriero, Angiola Spinetti, Valentina Zuccaro, Massimo Memoli, Alessia Giorgini, Mauro Viganò, Maria Grazia Rumi, Tiziana Re, Ombretta Spinelli, Maria Chiara Colombo, Tiziana Quirino, Barbara Menzaghi, Gianpaolo Lorini, Angelo Pan, Antonella D’Arminio Monforte, Elisabetta Buscarini, Aldo Autolitano, Paolo Bonfanti, Natalia Terreni, Gi

Subscribe to